Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,704 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
ZNF397 Deficiency Triggers TET2-Driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer.
Xu Y, Yang Y, Wang Z, Sjöström M, Jiang Y, Tang Y, Cheng S, Deng S, Wang C, Gonzalez J, Johnson NA, Li X, Li X, Metang LA, Mukherji A, Xu Q, Tirado CR, Wainwright G, Yu X, Barnes S, Hofstad M, Chen Y, Zhu H, Hanker AB, Raj GV, Zhu G, He HH, Wang Z, Arteaga CL, Liang H, Feng FY, Wang Y, Wang T, Mu P. Xu Y, et al. Among authors: deng s. Cancer Discov. 2024 Aug 2;14(8):1496-1521. doi: 10.1158/2159-8290.CD-23-0539. Cancer Discov. 2024. PMID: 38591846 Free PMC article.
The paracrine induction of prostate cancer progression by caveolin-1.
Lin CJ, Yun EJ, Lo UG, Tai YL, Deng S, Hernandez E, Dang A, Chen YA, Saha D, Mu P, Lin H, Li TK, Shen TL, Lai CH, Hsieh JT. Lin CJ, et al. Among authors: deng s. Cell Death Dis. 2019 Nov 4;10(11):834. doi: 10.1038/s41419-019-2066-3. Cell Death Dis. 2019. PMID: 31685812 Free PMC article.
Loss of CHD1 Promotes Heterogeneous Mechanisms of Resistance to AR-Targeted Therapy via Chromatin Dysregulation.
Zhang Z, Zhou C, Li X, Barnes SD, Deng S, Hoover E, Chen CC, Lee YS, Zhang Y, Wang C, Metang LA, Wu C, Tirado CR, Johnson NA, Wongvipat J, Navrazhina K, Cao Z, Choi D, Huang CH, Linton E, Chen X, Liang Y, Mason CE, de Stanchina E, Abida W, Lujambio A, Li S, Lowe SW, Mendell JT, Malladi VS, Sawyers CL, Mu P. Zhang Z, et al. Among authors: deng s. Cancer Cell. 2020 Apr 13;37(4):584-598.e11. doi: 10.1016/j.ccell.2020.03.001. Epub 2020 Mar 26. Cancer Cell. 2020. PMID: 32220301 Free PMC article.
Ectopic JAK-STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance.
Deng S, Wang C, Wang Y, Xu Y, Li X, Johnson NA, Mukherji A, Lo UG, Xu L, Gonzalez J, Metang LA, Ye J, Tirado CR, Rodarte K, Zhou Y, Xie Z, Arana C, Annamalai V, Liu X, Vander Griend DJ, Strand D, Hsieh JT, Li B, Raj G, Wang T, Mu P. Deng S, et al. Nat Cancer. 2022 Sep;3(9):1071-1087. doi: 10.1038/s43018-022-00431-9. Epub 2022 Sep 5. Nat Cancer. 2022. PMID: 36065066 Free PMC article.
Author Correction: Ectopic JAK-STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance.
Deng S, Wang C, Wang Y, Xu Y, Li X, Johnson NA, Mukherji A, Lo UG, Xu L, Gonzalez J, Metang LA, Ye J, Tirado CR, Rodarte K, Zhou Y, Xie Z, Arana C, Annamalai V, Liu X, Vander Griend DJ, Strand D, Hsieh JT, Li B, Raj G, Wang T, Mu P. Deng S, et al. Nat Cancer. 2022 Oct;3(10):1271. doi: 10.1038/s43018-022-00458-y. Nat Cancer. 2022. PMID: 36241729 Free PMC article. No abstract available.
Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer.
Li X, Wang Y, Deng S, Zhu G, Wang C, Johnson NA, Zhang Z, Tirado CR, Xu Y, Metang LA, Gonzalez J, Mukherji A, Ye J, Yang Y, Peng W, Tang Y, Hofstad M, Xie Z, Yoon H, Chen L, Liu X, Chen S, Zhu H, Strand D, Liang H, Raj G, He HH, Mendell JT, Li B, Wang T, Mu P. Li X, et al. Among authors: deng s. Cancer Cell. 2023 Aug 14;41(8):1427-1449.e12. doi: 10.1016/j.ccell.2023.06.010. Epub 2023 Jul 20. Cancer Cell. 2023. PMID: 37478850 Free PMC article.
ZNF397 Loss Triggers TET2-driven Epigenetic Rewiring, Lineage Plasticity, and AR-targeted Therapy Resistance in AR-dependent Cancers.
Xu Y, Wang Z, Sjöström M, Deng S, Wang C, Johnson NA, Gonzalez J, Li X, Metang LA, Tirado CR, Mukherji A, Wainwright G, Yu X, Yang Y, Barnes S, Hofstad M, Zhu H, Hanker A, He HH, Chen Y, Wang Z, Raj G, Arteaga C, Feng F, Wang Y, Wang T, Mu P. Xu Y, et al. Among authors: deng s. bioRxiv [Preprint]. 2023 Oct 27:2023.10.24.563645. doi: 10.1101/2023.10.24.563645. bioRxiv. 2023. Update in: Cancer Discov. 2024 Aug 2;14(8):1496-1521. doi: 10.1158/2159-8290.CD-23-0539. PMID: 37961351 Free PMC article. Updated. Preprint.
UBE2J1 is the E2 ubiquitin-conjugating enzyme regulating androgen receptor degradation and antiandrogen resistance.
Rodriguez Tirado C, Wang C, Li X, Deng S, Gonzalez J, Johnson NA, Xu Y, Metang LA, Sundar Rajan M, Yang Y, Yin Y, Hofstad M, Raj GV, Zhang S, Lemoff A, He W, Fan J, Wang Y, Wang T, Mu P. Rodriguez Tirado C, et al. Among authors: deng s. Oncogene. 2024 Jan;43(4):265-280. doi: 10.1038/s41388-023-02890-5. Epub 2023 Nov 29. Oncogene. 2024. PMID: 38030789 Free PMC article.
6,704 results